APA (7th ed.) Citation

Catto, J., Tran, B., Rouprêt, M., Gschwend, J., Loriot, Y., Nishiyama, H., . . . Steinberg, G. (2024). Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer. Annals of Oncology, 35(1), 98. https://doi.org/10.1016/j.annonc.2023.09.3116

Chicago Style (17th ed.) Citation

Catto, J.W.F, et al. "Erdafitinib in BCG-treated High-risk Non-muscle-invasive Bladder Cancer." Annals of Oncology 35, no. 1 (2024): 98. https://doi.org/10.1016/j.annonc.2023.09.3116.

MLA (9th ed.) Citation

Catto, J.W.F, et al. "Erdafitinib in BCG-treated High-risk Non-muscle-invasive Bladder Cancer." Annals of Oncology, vol. 35, no. 1, 2024, p. 98, https://doi.org/10.1016/j.annonc.2023.09.3116.